An 86-year-old Florida woman’s routine chest X-ray unexpectedly revealed an artifact of a bygone tuberculosis (TB) therapy: an oleothorax — a dense, calcified mass created decades earlier when mineral oil was instilled around a lung to intentionally collapse it. The finding, documented in a 2017 New England Journal of Medicine image report, is rare to see in modern practice but remains important for clinicians to recognize so it is not mistaken for cancer or another life‑threatening condition. NEJM
What doctors saw — and why it matters on an X‑ray
On radiographs, an old oleothorax typically appears as a well‑demarcated, often calcified pleural opacity in the upper chest. Historically, the oil mass was meant to keep diseased lung tissue collapsed; in some patients it was never removed and can persist for life. Reviews of legacy cases describe potential late complications — including restrictive breathing symptoms, lipoid pneumonia, infection, and very rare TB reactivation within the oil cavity — but many people remain asymptomatic and the finding is incidental. Recognizing this distinctive pattern can prevent unnecessary invasive biopsies and guide appropriate follow‑up. Respiration (open‑access review); Journal of Thoracic Imaging
How oleothorax worked — and why it fell out of use
Oleothorax was one form of “collapse therapy” used before modern antibiotics. Physicians instilled mineral or vegetable oil into the pleural space to compress the infected lobe, reduce oxygen availability to Mycobacterium tuberculosis, and allow cavities to close. The oil was usually drained after recovery, but some patients were lost to follow‑up and retained it indefinitely. As effective drug therapies arrived — notably isoniazid in 1952 and later second‑line agents such as ethionamide — collapse approaches (including oleothorax and extraperiosteal “plombage”) were abandoned because medicines worked better and the procedures carried risks. QJM; Britannica: Isoniazid
In the United States, TB mortality was still high in the early antibiotic era — nearly 20,000 deaths were recorded in 1953 — before falling steadily with drug treatment and public‑health control. CDC historical table
TB today: global burden and U.S. trends
TB remains a leading infectious killer worldwide. According to the World Health Organization, an estimated 1.25 million people died from TB in 2023 (including deaths among people living with HIV), and approximately 10.8 million people fell ill. With COVID‑19 receding, TB likely returned to the top spot among infectious causes of death that year. WHO Global TB Report 2024
In the United States, TB case counts declined for nearly three decades, dropped sharply in 2020, and have risen each year since. Provisional CDC data show 10,347 cases in 2024 — an 8 percent increase over 2023 and the highest since 2011. In 2024, 34 states and the District of Columbia reported increases, and about three‑quarters of cases occurred among people born outside the United States, consistent with prior years. TB remained uncommon but not trivial: the most recent finalized mortality data show 565 TB deaths in 2022 (about 0.2 per 100,000). CDC 2024 provisional data; CDC 2023 surveillance summary
One‑line takeaway: This unusual X‑ray is a reminder that past TB treatments can still surface in today’s clinics — and that TB itself remains a current public‑health concern, not just medical history.
How TB spreads and what to watch for
TB bacteria spread through the air when a person with contagious pulmonary TB coughs, speaks, or sings; tiny airborne particles (droplet nuclei) can linger for hours in poorly ventilated spaces. People with latent TB infection do not feel sick and cannot transmit the bacteria; those with active disease can. CDC: Causes and transmission
Common symptoms of active pulmonary TB include a persistent cough (three weeks or longer), chest pain, coughing up blood or sputum, fever, night sweats, fatigue, weight loss, and loss of appetite. Extrapulmonary TB may cause back pain, lymph‑node swelling, headache or confusion, and other site‑specific symptoms. Anyone with prolonged, unexplained respiratory symptoms should seek medical evaluation. CDC: Signs and symptoms
Treatment and prevention have advanced
Most drug‑susceptible TB is curable with a multi‑drug regimen guided by drug susceptibility testing and public‑health support. For drug‑resistant TB, the WHO now recommends all‑oral, shorter regimens for many patients: a 6‑month combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (the BPaLM regimen), or BPaL when fluoroquinolone resistance is present. These options have improved outcomes and reduced treatment time compared with older, longer regimens that required injectables. National programs adopt these recommendations as capacity allows. WHO TB Knowledge Sharing: BPaLM; WHO 2022 guideline update
In the United States, the Bacille Calmette‑Guérin (BCG) vaccine is not routinely used because of low overall risk and variable protection against adult pulmonary disease; it may be considered only in select high‑risk circumstances. Prevention focuses on finding and treating latent TB infection among people at increased risk, particularly close contacts of infectious TB and those with medical conditions that weaken immunity. CDC: BCG vaccine
Clinical context for the oleothorax finding
For radiologists, pulmonologists, and emergency clinicians evaluating older adults, an upper‑lobe pleural mass with peripheral calcification should prompt a review of TB history and consideration of historic collapse therapies (oleothorax or extraperiosteal plombage) in the differential. Prior oleothorax can mimic neoplasm on imaging; correlating with history and classic radiographic features may avert invasive procedures. When oleothorax is confirmed and the patient is asymptomatic, management is usually conservative, with attention to any late complications that merit intervention. Respiration (open‑access review)
For public‑health programs, the case underscores a dual reality: modern therapy has transformed TB care, yet durable legacies of earlier eras remain in patients’ bodies and medical records. Meanwhile, the United States has seen a post‑pandemic rise in cases tied to delayed diagnoses, increased travel and migration, and outbreaks in select jurisdictions, reinforcing the need to maintain core TB services — timely testing, contact investigations, and completion of treatment — to prevent transmission and deaths. CDC 2024 provisional data
If you want more on trends in infectious diseases and the policies shaping prevention, read more on Globally Pulse Health.
